Cited by 2,207Cancer Genomics and DiagnosticsBRCA gene mutations in cancerBreast Cancer Treatment Studies

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer

Open access

Dawson, Sarah-Jane, Tsui, Dana W.Y., Murtaza, Muhammed, Biggs, Heather, Rueda, Oscar M., Chin, Suet-Feung, Dunning, Mark J., Gale, Davina, Forshew, Tim, Mahler-Araujo, Betania, Rajan, Sabrina, Humphray, Sean, Becq, Jennifer, Halsall, David, Wallis, Matthew, Bentley, David, Caldas, Carlos, Rosenfeld, Nitzan·2013·New England Journal of Medicine

DOI 10.1056/nejmoa1213261

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The management of metastatic breast cancer requires monitoring of the tumor burden to determine the response to treatment, and improved biomarkers are needed. Biomarkers such as cancer antigen 15-3 (CA 15-3) and circulating tumor cells have been widely studied. However, circulating cell-free DNA carrying tumor-specific alterations (circulating tumor DNA) has not been extensively investigated or compared with other circulating biomarkers in breast cancer. METHODS: We compared the radiographic imaging of tumors with the assay of circulating tumor DNA, CA 15-3, and circulating tumor cells in 30 women with metastatic breast cancer who were receiving systemic therapy. We used targeted or whole-genome sequencing to identify somatic genomic alterations and designed personalized assays to quantify circulating tumor DNA in serially collected plasma specimens. CA 15-3 levels and numbers of circulating tumor cells were measured at identical time points. RESULTS: Circulating tumor DNA was successfully detected in 29 of the 30 women (97%) in whom somatic genomic alterations were identified; CA 15-3 and circulating tumor cells were detected in 21 of 27 women (78%) and 26 of 30 women (87%), respectively. Circulating tumor DNA levels showed a greater dynamic range, and greater correlation with changes in tumor burden, than did CA 15-3 or circulating tumor cells. Among the measures tested, circulating tumor DNA provided the earliest measure of treatment response in 10 of 19 women (53%). CONCLUSIONS: This proof-of-concept analysis showed that circulating tumor DNA is an informative, inherently specific, and highly sensitive biomarker of metastatic breast cancer. (Funded by Cancer Research UK and others.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1213261

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1994) · doi:10.1201/9780429246593 · Cited by 40,500
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1993) · doi:10.1007/978-1-4899-4541-9 · Cited by 21,230
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Self-citation
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,602
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Isolation of rare circulating tumour cells in cancer patients by microchip technology
Nagrath, S., Sequist, L. V. D., Maheswaran, S., Bell, D. W., Irimia, D., Ulkus, L., Smith, M. R., Kwak, E. L., Digumarthy, S. R., Muzikansky, A., et al. (2007) · Nature · doi:10.1038/nature06385 · Cited by 3,595
Cell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. �., & Pantel, K. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3066 · Cited by 2,897

Flagged first, then by citations

Show all 44 references

1 of the 44 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Lauro S, 1999, Anticancer Res, 19, 3511
Chen X, 1999, Clin Cancer Res, 5, 2297

Sorted by citations

Items 601–700 of 1,003

Harnessing liquid biopsies: Exosomes and ctDNA as minimally invasive biomarkers for precision cancer medicine
Bamodu, O. A., Chung, C., & Pisanic, T. R. (2023) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2023.100126 · Cited by 63
Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?
Polívka, J., Pešta, M., & Jankú, F. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1110021 · Cited by 57
Metastatic Breast Cancer
Sousa, B., Ribeiro, J. M., Ribnikar, D., & Cardoso, F. (2016) · Springer eBooks · doi:10.1007/978-3-319-46356-8_24 · Cited by 56
Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma
McEvoy, A. C., Calapre, L., Pereira, M. R., Giardina, T. M., Robinson, C., Khattak, M. A., Meniawy, T. M., Pritchard, A. L., Hayward, N. K., Amanuel, B., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20354 · Cited by 56
Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients
Park, G., Park, J. K., Son, D., Shin, S., Kim, Y. J., Jeon, H.-J., Lee, J., Park, W., Lee, K. H., & Park, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-30100-w · Cited by 57
Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis
Uesato, Y., Sasahira, N., Ozaka, M., Sasaki, T., Takatsuki, M., & Zembutsu, H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235623 · Cited by 56
Subclonal heterogeneity and evolution in breast cancer
Mavrommati, I., Johnson, F., Echeverria, G. V., & Natrajan, R. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00363-0 · Cited by 56
Circulating tumor DNA validity and potential uses in metastatic breast cancer
Amato, O., Giannopoulou, N., & Ignatiadis, M. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00626-6 · Cited by 64
Non-invasive pre-implantation genetic diagnosis of X-linked disorders
Assou, S., Aït‐Ahmed, O., Messaoudi, S. E., Thierry, A. R., & Hamamah, S. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2014.08.019 · Cited by 55
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers
Fujii, T., Barzi, A., Bianchi, A. S., Cassingena, A., Siravegna, G., Karp, D. D., Piha-Paul, S. A., Subbiah, V., Tsimberidou, A. M., Huang, H. J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2592 · Cited by 56
Application of single-cell technology in cancer research
Liang, S.-B., & Fu, L. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.04.001 · Cited by 56
Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing
Mansukhani, S., Barber, L. J., Kleftogiannis, D., Moorcraft, S. Y., Davidson, M., Woolston, A., Proszek, P., Griffiths, B. L., Fenwick, K., Herman, B., et al. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.289629 · Cited by 55
Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer
Nordgård, O., Tjensvoll, K., Gilje, B., & Søreide, K. (2018) · British journal of surgery · doi:10.1002/bjs.10782 · Cited by 57
Matched Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) of Tumor Tissue with Circulating Tumor DNA (ctDNA) Analysis: Complementary Modalities in Clinical Practice
Imperial, R. J. L., Nazer, M., Ahmed, Z., Kam, A. E., Pluard, T., Bahaj, W., Levy, M. A., Kuzel, T. M., Hayden, D. M., Pappas, S. G., et al. (2019) · Cancers · doi:10.3390/cancers11091399 · Cited by 56
Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers
Maia, M. C., Salgia, M. M., & Pal, S. K. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0297-9 · Cited by 56
Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer
Feng, W., Jia, N., Jiao, H., Chen, J., Chen, Y., Zhang, Y., Zhu, M., Zhu, C., Shen, L., & Long, W. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02722-8 · Cited by 53
Circulating Tumor DNA as a Biomarker for Monitoring Patients with Solid Cancers: Comparison with Standard Protein Biomarkers
Duffy, M. J., & Crown, J. P. (2022) · Clinical Chemistry · doi:10.1093/clinchem/hvac121 · Cited by 55
A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study
Tan, L., Tran, B., Tie, J., Markman, B., Ananda, S., Tebbutt, N. C., Michael, M., Link, E. K., Wong, S. Q., Chandrashekar, S., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3094 · Cited by 54
Self-citation
Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going
Mazzitelli, C., Santini, D., Corradini, A. G., Zamagni, C., Treré, D., Montanaro, L., & Taffurelli, M. (2023) · Diagnostics · doi:10.3390/diagnostics13071241 · Cited by 54
Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean?
Earl, H. M., Provenzano, E., Abraham, J., Dunn, J., Vallier, A.-L., Gounaris, I., & Hiller, L. (2015) · BMC Medicine · doi:10.1186/s12916-015-0472-7 · Cited by 54
Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer
Kruglyak, K. M., Lin, E., & Ong, F. S.-C. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_7 · Cited by 53
Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer
Parsons, H. A., Beaver, J. A., Cimino‐Mathews, A., Ali, S. M., Axilbund, J. E., Chu, D. T. W., Connolly, R. M., Cochran, R. L., Croessmann, S., Clark, T. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1543 · Cited by 54
The development of a liquid biopsy for head and neck cancers
Schmidt, H., Kulasinghe, A., Kenny, L., & Punyadeera, C. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.07.014 · Cited by 54
Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker
Rohanizadegan, M. (2018) · Cancer Genetics · doi:10.1016/j.cancergen.2018.02.002 · Cited by 54
Mutation and Methylation Analysis of Circulating Tumor DNA Can Be Used for Follow-up of Metastatic Colorectal Cancer Patients
Boeckx, N., de Beeck, K. O., Beyens, M., Deschoolmeester, V., Hermans, C., Clercq, P. D., Garrigou, S., Normand, C., Monsaert, E., Papadimitriou, K., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.02.006 · Cited by 54
Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era
Brothers, J. F., Hijazi, K., Mascaux, C., El‐Zein, R. A., Spitz, M. R., & Spira, A. E. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-168 · Cited by 53
The molecular tumor burden index as a response evaluation criterion in breast cancer
Yi, Z., Ma, F., Rong, G., Liu, B., Guan, Y., Li, J., Sun, X., Wang, W., Guan, X., Mo, H., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00662-9 · Cited by 53
Comparing the Diagnostic Performance of Quantitative PCR, Digital Droplet PCR, and Next-Generation Sequencing Liquid Biopsies for Human Papillomavirus–Associated Cancers
Naegele, S., Ruiz‐Torres, D. A., Zhao, Y., Goss, D., & Faden, D. L. (2023) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2023.11.007 · Cited by 53
Circulating Tumor DNA and Survival in Metastatic Breast Cancer
Dickinson, K., Sharma, A., Agnihotram, R. V., Altuntur, S., Park, M., Meterissian, S. H., & Burnier, J. V. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.31722 · Cited by 59
A population genetics perspective on the determinants of intra-tumor heterogeneity
Hu, Z., Sun, R., & Curtis, C. N. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.03.001 · Cited by 54
Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer
Jankú, F., Zhang, S., Waters, J., Liu, L., Huang, H. J., Subbiah, V., Hong, D. S., Karp, D. D., Fu, S., Cai, X., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0291 · Cited by 52
Cell-free DNA in cancer: current insights
Fettke, H., Kwan, E. M., & Azad, A. (2018) · Cellular Oncology · doi:10.1007/s13402-018-0413-5 · Cited by 53
High‐throughput isolation of circulating tumor DNA : a comparison of automated platforms
van Dessel, L. F., Vitale, S. R., Helmijr, J., Wilting, S. M., van der Vlugt‐Daane, M., Hoop, E. O., Sleijfer, S., Martens, J. W. M., Jansen, M. P. H. M., & Lolkema, M. P. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12415 · Cited by 58
Detection of Circulating Tumor DNA in Plasma: A Potential Biomarker for Esophageal Adenocarcinoma
Egyud, M., Tejani, M. A., Pennathur, A., Luketich, J. D., Sridhar, P., Yamada, E., Ståhlberg, A., Filges, S., Krzyzanowski, P. M., Jackson, J., et al. (2019) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2019.04.004 · Cited by 53
The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer
Jacob, S. L., Davis, A. A., Gerratana, L., Velimirovic, M., Shah, A. N., Wehbe, F., Katam, N., Zhang, Q., Flaum, L., Siziopikou, K. P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1566 · Cited by 56
Early detection of cancer using circulating tumor DNA: biological, physiological and analytical considerations
Bronkhorst, A. J., Ungerer, V., & Holdenrieder, S. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1700902 · Cited by 56
Plasma DNA-Based Molecular Diagnosis, Prognostication, and Monitoring of Patients With EWSR1 Fusion-Positive Sarcomas
Shukla, N. N., Patel, J. A., Magnan, H., Zehir, A., You, D., Tang, J., Meng, F., Samoila, A., Slotkin, E. K., Ambati, S. R., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00028 · Cited by 52
Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival
Kato, S., Schwaederlé, M. C., Fanta, P. T., Okamura, R., Leichman, L., Lippman, S. M., Lanman, R. B., Raymond, V. M., Talasaz, A., & Kurzrock, R. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00158 · Cited by 52
Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy
Magbanua, M. J. M., Hendrix, L. H., Hyslop, T., Barry, W. T., Winer, E. P., Hudis, C. A., Toppmeyer, D., Carey, L., Partridge, A. H., Pierga, J., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa113 · Cited by 52
Self-citation
Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study
Zhu, G., Liu, W., Tang, Z., Qu, W., Fang, Y., Jiang, X., Song, S., Wang, H., Tao, C., Zhou, P., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13105 · Cited by 52
DNA methylation biomarkers for noninvasive detection of triple‐negative breast cancer using liquid biopsy
Manoochehri, M., Borhani, N., Gerhäuser, C., Assenov, Y., Schönung, M., Hielscher, T., Christensen, B. C., Lee, M. K., Gröne, H., Lipka, D. B., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34337 · Cited by 54
A liquid biopsy for head and neck cancers
Schmidt, H., Kulasinghe, A., Perry, C., Nelson, C. C., & Punyadeera, C. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2016.1127758 · Cited by 52
Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients
Dietz, S., Schirmer, U. B., Mercé, C., von Bubnoff, N. C. C., Dahl, E., Meister, M. A., Muley, T., Thomas, M., & Sültmann, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161012 · Cited by 52
Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3
Tang, Z., Li, L., Shen, L., Shen, X., Ju, S., & Cong, H. (2018) · Laboratory Medicine · doi:10.1093/labmed/lmy019 · Cited by 52
Overview of the genetic basis toward early detection of breast cancer
Silva, S. D., Tennekoon, K. H., & Karunanayake, E. H. (2019) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s185870 · Cited by 56
Detection of ctDNA from Dried Blood Spots after DNA Size Selection
Heider, K., Wan, J. C. M., Hall, J. A. M., Belic, J., Boyle, S. E., Hudecova, I., Gale, D. G., Cooper, W. N., Corrie, P. G., Brenton, J. D., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa050 · Cited by 52
Self-citation
Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma
Bosse, K. R., Giudice, A. M., Lane, M. V., McIntyre, B., Schürch, P. M., Pascual-Pasto, G., Buongervino, S. N., Suresh, S., Fitzsimmons, A., Hyman, A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0287 · Cited by 51
Genetic profiling of cancer with circulating tumor DNA analysis
Lu, L., Bi, J., & Bao, L. (2018) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2017.11.006 · Cited by 55
Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma
Openshaw, M. R., Suwaidan, A. A., Ottolini, B., Fernández-García, D., Richards, C. J., Page, K., Guttery, D. S., Thomas, A., & Shaw, J. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-1002-8 · Cited by 52
Circulating free DNA as non-invasive diagnostic biomarker for childhood solid tumors
Kurihara, S., Ueda, Y., Onitake, Y., Sueda, T., Ohta, E., Morihara, N., Hirano, S., Irisuna, F., & Hiyama, E. (2015) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2015.08.033 · Cited by 52
Molecular Testing in Breast Cancer
Paoletti, C., & Hayes, D. F. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-070912-143853 · Cited by 53
Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer
Santarpia, L., Bottai, G., Kelly, C. M., Győrffy, B., Székely, B., & Pusztai, L. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0369 · Cited by 59
Differential Proteome Analysis of Extracellular Vesicles from Breast Cancer Cell Lines by Chaperone Affinity Enrichment
Griffiths, S., Cormier, M., Clayton, A., & Doucette, A. A. (2017) · Proteomes · doi:10.3390/proteomes5040025 · Cited by 51
Identification of cancer biomarkers of prognostic value using specific gene regulatory networks (GRN): a novel role of RAD51AP1 for ovarian and lung cancers
Chudasama, D., Bo, V., Hall, M., Anikin, V., Jeyaneethi, J., Gregory, J., Pados, G., Tucker, A., Harvey, A., Pink, R. C., et al. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx122 · Cited by 50
Cell-Free DNA Kinetics in a Pre-Clinical Model of Head and Neck Cancer
Muhanna, N., Grappa, M. A. D., Chan, H. H. L., Khan, T. M., Jin, C. S., Zheng, Y., Irish, J. C., & Bratman, S. V. (2017) · Scientific Reports · doi:10.1038/s41598-017-17079-6 · Cited by 51
Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA
Ye, Z., Wang, C., Wan, S., Mu, Z., Zhang, Z., Abu-Khalaf, M. M., Fellin, F., Silver, D. P., Neupane, M., Jaslow, R. J., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.012 · Cited by 50
Centrifugation affects the purity of liquid biopsy‐based tumor biomarkers
Rikkert, L. G., van der Pol, E., van Leeuwen, T. G. J. M., Nieuwland, R., & Coumans, F. A. W. (2018) · Cytometry Part A · doi:10.1002/cyto.a.23641 · Cited by 51
Relationship of circulating tumor cells and Epstein–Barr virus DNA to progression‐free survival and overall survival in metastatic nasopharyngeal carcinoma patients
You, R., Liu, Y., Lin, M. F., Huang, P., Tang, L., Zhang, Y., Pan, Y., Liu, W., Guo, W., Zou, X., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32380 · Cited by 51
Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women
Chung, T. K. H., Cheung, T. H., Yim, S. F., Yu, M. Y., Chiu, R. W. K., Lo, K. W. K., Lee, I. P. C., Wong, R. R. Y., Lau, K. K. M., Wang, V. W., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.05.038 · Cited by 52
Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers
Venesio, T., Siravegna, G., Bardelli, A., & Sapino, A. (2017) · Pathobiology · doi:10.1159/000473882 · Cited by 51
A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer
Politaki, E., Agelaki, S., Apostolaki, S., Hatzidaki, D., Strati, A. D., Koinis, F., Perraki, M., Saloustrou, G., Stoupis, G., Kallergi, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485115 · Cited by 50
Mutation Profiling of Malignant Lymphoma by Next-Generation Sequencing of Circulating Cell-Free DNA
Sun, P., Chen, C., Xia, Y., Wang, Y., Liu, P., Bi, X.-W., Shao, Y. W., Ou, Q.-X., Wu, X., Yang, H., et al. (2019) · Journal of Cancer · doi:10.7150/jca.27615 · Cited by 50
Detection of disseminated tumor cells in bone marrow predict late recurrences in operable breast cancer patients
Tjensvoll, K., Nordgård, O., Skjæveland, M., Oltedal, S., Janssen, E. A. M., & Gilje, B. (2019) · BMC Cancer · doi:10.1186/s12885-019-6268-y · Cited by 50
Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients
Charo, L. M., Eskander, R. N., Okamura, R., Patel, S. P., Nikanjam, M., Lanman, R. B., Piccioni, D. E., Kato, S., McHale, M. T., & Kurzrock, R. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12791 · Cited by 50
Assessing the Concordance of Genomic Alterations between Circulating-Free DNA and Tumour Tissue in Cancer Patients
Jahangiri, L., & Hurst, T. P. (2019) · Cancers · doi:10.3390/cancers11121938 · Cited by 50
Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
Lapin, M., Edland, K. H., Tjensvoll, K., Oltedal, S., Austdal, M., Garresori, H., Rozenholc, Y., Gilje, B., & Nordgård, O. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3526 · Cited by 49
Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer
Xia, S., Kohli, M., Du, M., Dittmar, R. L., Lee, A., Nandy, D. K., Yuan, T., Guo, Y., Wang, Y., Tschannen, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3845 · Cited by 49
Realizing the Potential of Plasma Genotyping in an Age of Genotype-Directed Therapies
Luke, J. J., Oxnard, G. R., Paweletz, C. P., Camidge, D. R., Heymach, J. V., Solit, D. B., Johnson, B. E., & for the Cell Free DNA Working Group (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju214 · Cited by 48
Individualized Mutation Detection in Circulating Tumor DNA for Monitoring Colorectal Tumor Burden Using a Cancer-Associated Gene Sequencing Panel
Sato, K. A., Hachiya, T., Iwaya, T., Kume, K., Matsuo, T., Kawasaki, K., Abiko, Y., Akasaka, R., Matsumoto, T., Otsuka, K., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146275 · Cited by 51
Use of cell free DNA in breast oncology
Canzoniero, J. V., & Park, B. H. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.03.006 · Cited by 50
Efficient Purification and Release of Circulating Tumor Cells by Synergistic Effect of Biomarker and SiO2@Gel‐Microbead‐Based Size Difference Amplification
Huang, Q., Cai, B., Chen, B., Rao, L., He, Z., He, R., Guo, F., Zhao, L., Kondamareddy, K. K., Liu, W., et al. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201500981 · Cited by 49
Circulating tumor DNA in hepatocellular carcinoma: trends and challenges
Tang, J., Feng, Y.-L., Guo, T., Xie, A., & Cai, X. (2016) · Cell & Bioscience · doi:10.1186/s13578-016-0100-z · Cited by 49
Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma
Payne, K. F. B., Spruce, R. J., Beggs, A. D., Sharma, N., Kong, A. H., Martin, T., Parmar, S., Praveen, P., Nankivell, P., & Mehanna, H. M. (2018) · Head & Neck · doi:10.1002/hed.25140 · Cited by 49
Microfluidic extraction and digital quantification of circulating cell-free DNA from serum
Perez‐Toralla, K., Pereiro, I., Garrigou, S., Federico, F. D., Proudhon, C., Bidard, F., Viovy, J., Taly, V., & Descroix, S. (2019) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2019.01.159 · Cited by 49
Pharmacodynamic Biomarkers: Falling Short of the Mark?
Gainor, J. F., Longo, D. L., & Chabner, B. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3132 · Cited by 51
Size distribution of cell-free DNA in oncology
Udomruk, S., Orrapin, S., Pruksakorn, D., & Chaiyawat, P. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103455 · Cited by 49
The Role of Cell-Free DNA in Cancer Treatment Decision Making
Telekes, A., & Horváth, A. (2022) · Cancers · doi:10.3390/cancers14246115 · Cited by 50
Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Davis, A. A., Luo, J. R., Zheng, T., Dai, C., Dong, X., Tan, L., Suresh, R., Ademuyiwa, F. O., Rigden, C. E., Rearden, T. P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2177 · Cited by 50
Detection of Clonal and Subclonal Copy-Number Variants in Cell-Free DNA from Patients with Breast Cancer Using a Massively Multiplexed PCR Methodology
Kırkızlar, E., Zimmermann, B. G., Constantin, T. P., Swenerton, R., Hoang, B., Wayham, N. P., Babiarz, J., Demko, Z., Pelham, R. J., Kareht, S., et al. (2015) · Translational Oncology · doi:10.1016/j.tranon.2015.08.004 · Cited by 48
Chromosomal Instability in Cell-Free DNA Is a Serum Biomarker for Prostate Cancer
Schütz, E., Akbari, M. R., Beck, J., Urnovitz, H. B., Zhang, W., Bornemann-Kolatzki, K., Mitchell, W. M., Nam, R. K., & Narod, S. A. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.226571 · Cited by 50
Noninvasive diagnosis and monitoring of mutations by deep sequencing of circulating tumor DNA in esophageal squamous cell carcinoma
Luo, H., Li, H., Hu, Z., Wu, H., Liu, C., Li, Y., Zhang, X., Lin, P., Hou, Q., Ding, G., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.02.011 · Cited by 48
Circulating long non‐coding HOX transcript antisense intergenic ribonucleic acid in plasma as a potential biomarker for diagnosis of breast cancer
Zhang, Y., Zhang, K., Luo, Z., Liu, L., Wu, L., & Liu, J. (2016) · Thoracic Cancer · doi:10.1111/1759-7714.12373 · Cited by 48
Future of Liquid Biopsies With Growing Technological and Bioinformatics Studies: Opportunities and Challenges in Discovering Tumor Heterogeneity With Single-Cell Level Analysis
Ramalingam, N., & Jeffrey, S. S. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000308 · Cited by 48
Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer
Clatot, F., Perdrix, A., Beaussire, L., Lequesne, J., Lévy, C., Emile, G., Bubenheim, M., Lacaille, S., Calbrix, C., Augusto, L., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01290-x · Cited by 48
Decreased serum cell-free DNA levels in rheumatoid arthritis
Dunaeva, M., Buddingh’, B. C., Toes, R. E. M., Luime, J. J., Lubberts, E., & Pruijn, G. J. M. (2015) · Autoimmunity Highlights · doi:10.1007/s13317-015-0066-6 · Cited by 48
Pathophysiology of ctDNA Release into the Circulation and Its Characteristics: What Is Important for Clinical Applications
Papadopoulos, N. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-26439-0_9 · Cited by 49
Standardized procedure to measure the size distribution of extracellular vesicles together with other particles in biofluids with microfluidic resistive pulse sensing
Cimorelli, M., Nieuwland, R., Varga, Z., & van der Pol, E. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249603 · Cited by 46
Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis
Valenza, C., Saldanha, E. F., Gong, Y., Placido, P. D., Gritsch, D., Ortiz, H., Trapani, D., Conforti, F., Cremolini, C., Peters, S., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.03.019 · Cited by 52
Breast cancer circulating biomarkers: advantages, drawbacks, and new insights
on behalf of the Solid Tumor Working Party of European Blood and Marrow Transplantation Society (EBMT), Ravelli, A., Reuben, J. M., Lanza, F., Anfossi, S., Cappelletti, M. R., Zanotti, L., Gobbi, A., Senti, C., Brambilla, P., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-3944-7 · Cited by 49
Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls
Xia, S., Huang, C., Le, M., Dittmar, R. L., Du, M., Yuan, T., Guo, Y., Wang, Y., Wang, X., Tsai, S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.07.002 · Cited by 47
MultiplexKRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction
Jankú, F., Huang, H. J., Fujii, T., Shelton, D. N., Madwani, K., Fu, S., Tsimberidou, A. M., Piha-Paul, S. A., Wheler, J. J., Zinner, R., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw670 · Cited by 48
Liquid biopsy: unlocking the potentials of cell-free DNA
Chu, D. T. W., & Park, B. H. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2137-8 · Cited by 50
Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer
Chimonidou, M., Strati, A. D., Malamos, N., Kouneli, S., Georgoulias, V., & Lianidou, E. S. (2017) · Oncotarget · doi:10.18632/oncotarget.18679 · Cited by 47
Genetic Characterization of Brain Metastases in the Era of Targeted Therapy
Han, C. H., & Brastianos, P. K. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00230 · Cited by 48
Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test
González‐Billalabeitia, E., Conteduca, V., Wetterskog, D., Jayaram, A., & Attard, G. (2018) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-018-0098-x · Cited by 49
The Role of Exosomes in Breast Cancer Diagnosis
Piombino, C., Mastrolia, I., Omarini, C., Candini, O., Dominici, M., Piacentini, F., & Toss, A. (2021) · Biomedicines · doi:10.3390/biomedicines9030312 · Cited by 48
Leveraging the Fragment Length of Circulating Tumour DNA to Improve Molecular Profiling of Solid Tumour Malignancies with Next-Generation Sequencing: A Pathway to Advanced Non-invasive Diagnostics in Precision Oncology?
Underhill, H. R. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00534-6 · Cited by 47
Serum mitochondrial tsRNA serves as a novel biomarker for hepatocarcinoma diagnosis
Zhan, S., Yang, P., Zhou, S., Xu, Y., Xu, R. C., Liang, G., Zhang, C., Chen, X., Yang, L., Jin, F., et al. (2022) · Frontiers of Medicine · doi:10.1007/s11684-022-0920-7 · Cited by 46
Accurate detection of circulating tumor DNA using nanopore consensus sequencing
Marcozzi, A., Jager, M., Elferink, M., Straver, R., van Ginkel, J. H., Peltenburg, B., Chen, L., Renkens, I., van Kuik, J., Terhaard, C. H. J., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00272-y · Cited by 50
Nanoelectromechanical Chip (NELMEC) Combination of Nanoelectronics and Microfluidics to Diagnose Epithelial and Mesenchymal Circulating Tumor Cells from Leukocytes
Hosseini, S. A., Abdolahad, M., Zanganeh, S., Dahmardeh, M., Gharooni, M., Abiri, H., Alikhani, A., Mohajerzadeh, S., & Mashinchian, O. (2016) · Small · doi:10.1002/smll.201502808 · Cited by 46

Authors: Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., Rajan, S., Humphray, S., Becq, J., Halsall, D., Wallis, M., Bentley, D., Caldas, C., & Rosenfeld, N.
Affiliations: University of Cambridge (GB)
National Health Service (GB)
ORCID: Dawson, Sarah-Jane
Tsui, Dana W.Y.
Murtaza, Muhammed
Biggs, Heather
Rueda, Oscar M.
Chin, Suet-Feung
Dunning, Mark J.
Gale, Davina
Forshew, Tim
Mahler-Araujo, Betania
Humphray, Sean
Halsall, David
Wallis, Matthew
Caldas, Carlos
Rosenfeld, Nitzan
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2013-03-28
Volume: 368
Issue: 13
Pages: 1199-1209
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1213261
OpenAlex: W2140575188
Cited by: 2,207
References: 44
Citations by year: 2026: 86 · 2025: 96 · 2024: 106 · 2023: 109 · 2022: 169 · 2021: 180 · 2020: 197 · 2019: 220 · 2018: 197 · 2017: 224 · 2016: 204 · 2015: 195 · 2014: 135 · 2013: 82
FWCI: 72.15
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Funders: Cancer Research UK (11906, 16942, 22310)
National Institute for Health and Care Research (NF-SI-0611-10154)
NIHR Cambridge Biomedical Research Centre
Cancer Research UK Cambridge Institute, University of Cambridge
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: circulating tumor DNA, metastatic breast cancer, liquid biopsy, CA15-3, circulating tumor cells, treatment response monitoring, tumor burden, somatic alterations, circulating biomarkers, early detection of treatment response
MeSH terms: Breast Neoplasms, DNA, Neoplasm, Female, Humans, Mutation, Neoplasm Metastasis, Prognosis, Radiography, Sensitivity and Specificity, Biomarkers, Tumor, Sequence Analysis, DNA, Mucin-1, Tumor Burden, Genome-Wide Association Study

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks